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Abstract
Combination immunotherapy (CIT) is currently applied as a treatment for different cancers
and is proposed as a cure strategy for chronic viral infections. Whether such therapies are
efficient during an acute infection remains elusive. To address this, inhibitory receptors were
blocked and regulatory T cells depleted in acutely Friend retrovirus-infected mice. CIT
resulted in a dramatic expansion of cytotoxic CD4+ and CD8+ T cells and a subsequent
reduction in viral loads. Despite limited viral replication, mice developed fatal immunopathol-
ogy after CIT. The pathology was most severe in the gastrointestinal tract and was mediated
by granzyme B producing CD4+ and CD8+ T cells. A similar post-CIT pathology during
acute Influenza virus infection of mice was observed, which could be prevented by vaccina-
tion. Melanoma patients who developed immune-related adverse events under immune
checkpoint CIT also presented with expanded granzyme-expressing CD4+ and CD8+ T cell
populations. Our data suggest that acute infections may induce immunopathology in
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Author summary
Combination immunotherapy (CIT) directed against checkpoint mechanisms has been
approved for the therapy of cancers and is proposed for the treatment of chronic infec-
tions. In cancer therapy patients often develop severe immunopathology under CIT. Here
we show that acute viral infections (Friend retrovirus and Influenza virus) posed a signifi-
cant threat during CIT in mice. The strong activation of cytotoxic T cells after an acute
viral infection seemed to lack couterregulation during CIT, which resulted in lethal
immunopathology. In case of an Influenza virus infection this could be prevented by vac-
cination prior to CIT. The expansion of CD4+ and CD8+ T cells expressing cytotoxic
molecules were also observed in melanoma patients treated with two checkpoint blockers.
Thus, these patients might also be at risk of developing severe immunopathology during
an otherwise harmless acute viral infection. This should to be taken into account when
cancer patients are undergoing CIT.
Introduction
Cytotoxic CD8+ T cells are crucial for the control of tumor cells and acute viral infections.
However, during chronic viral infections, like HIV or HCV, these cells become dysfunctional
or “exhausted” [1]. The studies of Dr. Ahmed‘s group [2] demonstrated that signaling from
the programmed death receptor (PD-1) expressed on LCMV specific CD8+ T cells is a central
mechanism regulating the development of T cell dysfunction during chronic viral infections.
Blocking the PD-1/PD-L1 interaction and/or other inhibitory receptors, like Tim-3, therefore
results in improved control of chronic infections. These studies and previous work in tumor
mouse models [3,4] paved the way to develop new immunotherapies against certain human
cancers, as T cell dysfunction is also a hallmark of many malignant diseases [5]. The clinical
success of these immunotherapies has been outstanding for some cancer entities treatment of
melanoma, non-small cell lung cancer, renal cell carcinoma, colorectal cancer, hepatocellular
carcinoma, Hodgkin lymphoma and others [6].
Recently, it became evident that activated virus-specific CD8+ T cells also express PD-1 and
other inhibitory receptors in the acute phase of viral infections [7–9]. During this phase, T
cells are not dysfunctional, but inhibitory receptors seem to regulate the overall magnitude of
the T cell response. Thus, the treatment of mice with anti-PD-L1 or anti-PD-1 antibodies
enhanced the magnitude of antiviral immune responses during acute infections and improved
virus control [9,10]. Experiments with PD-1 or PD-L1 KO mice also demonstrated enhanced
antiviral CD8+ T cell response against acute viral infections [11–13]. Thus, inhibitory recep-
tors have important functions in regulating antiviral cytotoxic T cell responses during acute
and chronic viral infections.
Previously, others and we showed that also regulatory T cells (Tregs) contribute to the
exhaustion of the T cell response during chronic infections [14]. Tregs are a population of
forkhead box P3 (Foxp3) expressed lymphocytes which suppress effector CD4+ and CD8+ T
cells to prevent the development of autoimmunity, but they also suppress T cell responses dur-
ing infectious diseases [15] and different cancers [16]. The suppression of antiviral T cell
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responses by Tregs was first described in studies using the Friend retrovirus (FV) infection of
mice [17]. FV is a haematotropic retroviral complex that induces erythroleukemia in suscepti-
ble mice. In contrast, resistant strains, like C57BL/6 mice that were used in the current study,
develop potent immune responses during acute infection that allow protection from leukemia,
but they establish a life-long chronic infection when challenged with a high dose of the virus
[18,19]. During chronic FV infection, transient depletion of Tregs reactivated exhausted CD8+
T cells and thereby significantly reduced chronic viral set points [20]. Treg-mediated suppres-
sion of effector T cell responses was also observed in chronic infections of humans, including
HIV and HCV [21]. Similar results were obtained during acute FV infection in which deple-
tion of Tregs resulted in enhanced effector T cell functions and decreased viral loads [22,23].
However, in each experimental treatment alone, the blocking of the PD-1/PD-L1 pathway or
Treg ablation did not result in complete viral clearance during acute FV infection, and thus
chronic infection could still develop. Therefore, combining the two therapies might be a prom-
ising approach to further augment the effects of immune checkpoint blockers in an acute ret-
roviral infection.
Indeed, recent studies showed that the effect of immunotherapy with anti-PD-L1 can be
potentiated by combining it with other treatments targeting another mechanism of immuno-
regulation [24]. For chronic viral infections this has been demonstrated in vivo using two dif-
ferent mouse models. The effect of anti-PD-L1 treatment of chronic FV infection was
significantly enhanced after additional Treg depletion [25]. The combination treatment
resulted in an expansion of cytotoxic CD8+ T cells and a reduction of FV loads in infected
organs. Similar results were obtained in persistent LCMV infection [26], and in LP-BM5
murine leukemia retrovirus induced acquired immunodeficiency syndrome termed murine
AIDS (MAIDS)[27]. In mice, which received combined treatment with anti-PD-L1 antibodies
and depletion of Tregs, the reduction in chronic viral loads was significantly greater than with
either treatment alone. Thus, combination therapies targeting inhibitory receptors and Tregs
at the same time have been suggested for the therapy of infectious diseases and cancers in
many recent publications. In fact, the very successful combination therapy in malignant mela-
noma patients using anti-PD-L1 plus anti-CTLA-4 antibodies was reported to block inhibitory
receptors as well as Treg functions [28,29].
The initial idea of the current study was to combine the therapeutic depletion of Tregs with
the blockade of PD-L1 and Tim-3 as treatment during acute FV infection, with the ultimate
goal to prevent the establishment of viral chronicity. Our data indeed shows a massive expan-
sion of cytotoxic T cells followed by a significant reduction or even complete elimination of
FV. However, all mice receiving combination treatment developed fatal systemic immunopa-
thology shortly after the therapy. To verify these findings with a virus that has more relevance
for human infections, we repeated the experiment with Influenza A (IA) virus. Again all ani-
mals died of immunopathology after immunotherapy, but could be rescued by IA vaccination.
The current study supplies important evidence that an otherwise harmless acute viral infection
can result in severe pathology if immune checkpoints are manipulated. This needs to be taken
into account, when cancer patients are considered to be treated with combination
immunotherapy.
Results
Combination therapy activates cytotoxic T cells and reduces acute viral
loads
Since combination immunotherapy targeting Tregs and inhibitory receptors previously
showed high efficacy for the treatment of chronic FV [25] and LCMV [26] infection, we
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investigated if such treatment during acute FV infection may result in complete elimination of
the virus and thus prevents the establishment of viral chronicity. For the current experiments
the DEREG strain of mice with C57BL/6 background was used that express diphtheria toxin
(DT) receptor under the control of the Foxp3 promoter [30]. Injection of DT resulted in the
specific elimination of Tregs, which was combined with an injection of blocking antibodies
against PD-L1 and Tim-3. The treatment was performed during the second week of FV infec-
tion (day 7 to 13) and the spleens were analyzed directly after treatment on day 14 after infec-
tion (Fig 1A). Mice were treated with either treatment alone (Treg depletion or inhibitory
receptor block with the two antibodies) or a combination of the two.
Cytotoxic effector CD8+ T cells are the main immune cell population responsible for the
control of FV during acute infection [31] and the total population of effector CD8+ T cells
responding to FV infection can be determined by the expression of the activation-associated
glycoform of CD43 [31,32]. The highest frequencies of CD8+CD43+ T cells were observed in
the group of mice receiving combination therapy, which were significantly higher compared
to individual treatments (Fig 1B, S1A Fig). Interestingly, the frequencies of CD8+ T cells spe-
cific for the immunodominant FV epitope Db-GagL [33] (Tetr+) were enhanced after the anti-
body or DT treatment alone, but the combination of the two did not further increase
percentages of virus-specific CD8+ T cells (Fig 1C, S1B Fig). CD8+ T cells contain granula
with cytotoxic molecules, like the serine protease granzyme B (GzmB). Percentages of CD8
+ GzmB+ T cells were significantly enhanced in mice receiving combination immunotherapy
in comparison to any monotherapy (Fig 1D, S1C Fig). Moreover, we also analyzed whether
immunotherapy induces cytotoxic CD4+ T cells. Previous studies reported that during acute
FV infection virus-specific CD4+ T cells develop a Th1 or TfH-like phenotype with no signs of
cytotoxic activity [34, 35]. Accordingly, GzmB expression in CD4+ T cells was not detected in
FV-infected mice or animals receiving either Treg or inhibitory receptor therapy, but approxi-
mately 10% of the CD4+ T cells from mice on combination therapy started to produce GzmB
(Fig 1E, S1D Fig). The augmented cytotoxic T cell responses after combination treatment were
expected to result in reduced viral loads in these mice. Indeed, it was associated with a dra-
matic reduction of FV loads (Fig 1F) and in some mice of this group (about 25%) infectious
virus was no longer detectable with an infectious center assay. These data suggested that com-
bination immunotherapy may be a promising approach for the treatment of acute virus infec-
tions, which may prevent the establishment of viral chronicity.
Combination therapy induces immunopathology during acute FV infection
In order to test if combination treatment can indeed prevent viral chronicity the treatment
protocol during the acute phase of FV infection was repeated, but the analysis of the mice was
scheduled for week 6 post infection (chronic phase). Surprisingly, all mice (12 out of 12) that
received the combination therapy developed lethal pathology and were sacrificed between day
5 and 7 post treatment (Fig 2A). Mice from the other groups survived without any symptoms
of morbidity, except one mouse (1 out of 12) in the Treg depletion group developed pathology.
Also control mice from a group of non-infected animals receiving combination therapy sur-
vived, indicating that only the combination of acute FV infection with two checkpoint block-
ing therapies was fatal for the mice. We therefore investigated why mice in the combination
therapy arm died despite low viral load and indication of a cure. In order to address this ques-
tion, pathological and immunological studies were performed on day 4 after treatment (18
days after infection). Close observation of mice showed reduced motility, a reduced consump-
tion of food, and apathy in the group of FV-infected mice receiving the combination treat-
ment. The animals from all other groups did not show any abnormal behavior. An autopsy of
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Fig 1. Reduced levels of FV and enhanced number of CD8+ and CD4+ T cells producing GzmB after Treg depletion and/or
inhibitory pathway blockage in acutely infected mice. DEREG mice were infected with FV and treated with DT and/or blocking
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mice after combination therapy revealed systemic lymphadenopathy (Fig 2B). The pathologi-
cal analysis showed hepatitis, pancreatitis, and gastritis in mice after FV infection and combi-
nation treatment (S2 Fig). Moreover, the small intestine of these mice was swollen and filled
with melena (Fig 1C). The intestines of mice from the different groups were isolated and char-
acterized by immunohistochemical staining for the infiltration of T lymphocytes. The intesti-
nal crypts of all analyzed mice contained CD4+ and CD8+ T cells (S3 Fig). The numbers of
CD4+ T cells in these crypts were much higher than those of CD8+ T cells, but no obvious
antibodies against PD-L1 and TIM-3 as indicated (A). Flow cytometry was used for the determination of spleen CD8+ T cells which
are expressing CD43 (B), positive for MHC class I H2-Db tetramers specific for FV GagL peptide (Tetr+) (C), and producing the
GzmB (D), and the percentages of CD4+ T cells producing the GzmB (E). Spleens of chronically FV-infected mice from the different
treatment groups were analyzed for viral loads by infectious center assays one day after termination of treatment (F). Each dot
represents an individual mouse. Data were pooled from 3 to 5 independent experiments with similar results. Statistically significant
differences are indicated by asterisks (� < 0.05; �� < 0.005; ��� < 0.0005; one-way ANOVA with a Tukey post-test).
https://doi.org/10.1371/journal.ppat.1008340.g001
Fig 2. The death of FV infected mice within one week after Treg depletion and blocking of inhibitory pathways. DEREG mice were infected with FV and were
treated with DT and/or blocking antibodies against PD-L1 and TIM-3 as indicated during the second week of infection (A). Lymphadenopathy (B) and pathology of the
intestine (C) in mice after Treg depletion and treatment with anti-PD-L1 and anti-TIM-3. The percentages of CD8+GzmB+ (D) or CD4+GzmB+ (E) T cells isolated
from the intestine of mice infected with FV and treated with DT and/or blocking antibodies against PD-L1 and TIM-3. Data were pooled from 3 to 5 independent
experiments with similar results. Statistically significant differences are indicated by asterisks (� < 0.05; �� < 0.005; one-way ANOVA with a Tukey post-test).
https://doi.org/10.1371/journal.ppat.1008340.g002
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differences between the therapy groups were found. In the following experiments T cells from
the intestinal lamina propria were isolated and characterized for GzmB expression. The com-
bination treatment led to a significantly higher frequency of intestinal CD8+ T cells producing
the cytotoxic molecule GzmB in FV-infected mice or mice receiving only blocking antibodies
against inhibitory receptors compared to non-treated FV-infected animals (Fig 2D). Similarly,
high frequencies of CD8+ GzmB+ T cells were found in only Treg depleted mice. In contrast,
an enhanced frequency of GzmB producing CD4+ T cells in the lamina propria was only
found in FV-infected mice after combination therapy (Fig 2E). In all other groups of animals,
the numbers of CD4+ T cells producing GzmB were unchanged after treatment.
The pathology of the intestine was therefore associated with activation of the immune sys-
tem and systemic lymphatic hyperplasia (Fig 2B). In order to determine the systemic activation
of T cells, inguinal lymph nodes (ILN) were isolated and characterized by flow cytometry (S4
Fig). Percentages of CD8+ and CD4+ T cells expressing the transcriptions factor of effector T
cells T-bet, the marker of proliferation Ki67, and surface molecules associated with an effector
T cells phenotype (CD44+, CD43+, CD11a+, CD62L-, CD127-, CD69+) were strongly
enhanced after combination therapy compared to all other groups. The ILN are localized sub-
cutaneously and drain neither FV-infected organs nor organs with immunopathology. Thus,
the expansion of activated T cells in ILN reflects the systemic activation of T cells after combi-
nation therapy. In the following experiments T cell functions were analyzed in the ILN and in
mesenteric lymph nodes (MesLN). MesLN drain the gut and the activity of T cells in these
LN reflects the T cell response in the intestine. The population of effector CD8+CD43+ T cells
was significantly expanded in the ILN and MesLN after combination treatment (Fig 3A). How-
ever, no dramatic difference between the groups was found for numbers of virus-specific CD8
+Tetr+ T cells (Fig 3B). Eomesodemin (Eomes) is a transcription factor necessary for the dif-
ferentiation of cytotoxic CD4+ T cells [36, 37] and cytotoxic CD8+ T cells [38]. The combina-
tion treatment resulted in the highest detectable numbers of CD8+ T cells expressing Eomes
(Fig 3C) or the cytotoxic molecule GzmB in both LN (Fig 3D), indicating that the cytotoxic
program in CD8+ T cells is efficiently stimulated by the combination therapy.
To study CD4+ T cells responses during acute FV infection, we used the CD43+CD62L-
phenotype that efficiently characterizes effector CD4+ T cells [34]. The depletion of Tregs
alone or in combination with antibody treatment led to an expansion of CD4+ T cells with this
phenotype in LN (Fig 3E). However, similar to the virus-specific CD8+ T cell response no dra-
matic expansion of CD4+ Tetr II+ T cells specific for MHC class-II Ab restricted envelope epi-
tope of FV was detected in any of the groups (Fig 3F). The analysis of cytotoxic CD4+ T cells
(Eomes+ or GzmB+ cells) showed significantly enhanced numbers of GzmB expressing CD4
+ cells after combination treatment in both LN compared to either treatment alone (Fig 3H),
whereas the differences for Eomes expression were not so striking between the groups (Fig
3G).
To follow pathology the body weight of mice was compared between FV-infected mice, FV-
infected mice receiving combination therapy, and FV-infected mice with combination therapy
and T cell depletion. Acute FV infection alone did not result in any weight loss, whereas the
combination treatment induced severe weight loss (Fig 4A), so that mice had to be euthanized.
At 4 days post treatment the mean body weight of these mice was significantly lower than that
of animals, which were additionally depleted for CD4+ and CD8+ T cells. Interestingly, the
depletion of only CD4+ or only CD8+ T cells alone after combination treatment did not
change the pathology in comparison to non-depleted mice. The results indicate that both T
cell populations were indeed involved in immunopathology after the checkpoint blocking
therapy during acute viral infection. The fact that T cell depleted mice still presented with a
moderate weight loss after combination treatment might be explained by the incomplete
PLOS PATHOGENS Combination immunotherapy during acute viral infections results in lethal immunopathology
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008340 March 30, 2020 7 / 30
PLOS PATHOGENS Combination immunotherapy during acute viral infections results in lethal immunopathology
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008340 March 30, 2020 8 / 30
depletion (spleen: 83% CD4+ and 94% CD8+ T cells; lymph nodes: 56% CD4+ and 74% CD8
+ T cells) due to the strong activation of T cells. In order to show that GzmB dependent cyto-
toxicity played a key role in the development of immunopathology, DEREG mice were crossed
with GzmB KO animals. DEREG-GzmB KO mice were then infected with FV and received
combination therapy. Infected DEREG-GzmB KO mice did not lose any weight after the treat-
ment, indicating that GzmB was critically involved in the pathology.
Since virus-specific CD4+ and CD8+ T cells that recognize immunodominant epitopes of
FV did not significantly expand after combination therapy (Fig 1), it was possible that non-
virus-specific cytotoxic CD4+ and CD8+ T cells might expand due to the therapy. To test this
an in vitro killing assay for re-directed T cells was performed (Fig 4B) [39]. Mastocytoma P815
cells, which express Fc receptors were loaded with anti-CD3 antibodies and used as targets for
killing. The re-directed killing of the P815 cells was induced after conjugation of cytotoxic T
cells through the anti-CD3 antibody. The CD8+ and CD4+ T cells for this assay were separated
from spleens of naïve mice, FV-infected mice, and from FV-infected mice receiving combina-
tion therapy. CD4+ and CD8+ T cells isolated from FV-infected, treated mice showed signifi-
cantly higher cytotoxicity than cells isolated from FV-infected mice, with the highest killing
seen in cultures containing a mixture of CD4+ and CD8+ T cells. Control cells, isolated from
naïve mice did not show any cytotoxic function.
To further understand differences in the factors associated with this particular phenotype
in animals receiving combination therapy, a global analysis of the CD4+ and CD8+ T cell pro-
teome was performed by label-free quantification using liquid chromatography and tandem
mass spectrometry (LC-MS/MS). At 18 days post infection CD3+CD8+CD43+ T cells and
CD3+CD4+CD43+CD62L- T cells were sorted from the spleen of FV-infected DEREG mice
and from infected DEREG mice treated with DT plus anti-PD-L1/Tim-3 antibodies. Cells
were lysed and subjected to proteome analysis covering a total of 1889 proteins (S1 Table).
From all detected proteins, the expression of 104 molecules was significantly enhanced and the
expression of 91 proteins was reduced in CD8+ T cells isolated from mice receiving combina-
tion therapy (Fig 4C). Of these differently regulated proteins, 24 were associated with pathways
of the immune system. In sorted CD4+ T cells from mice receiving combination therapy, the
expression of 158 proteins was reduced and the expression of 81 proteins was enhanced in
comparison to CD4+ T cells from non-treated FV-infected mice (Fig 4D). From those, 29 pro-
teins were linked with the processes of the immune system. The following clustering analysis
with the Gene Ontology enrichment tool (GO analysis) of differently expressed proteins
showed that in both CD8+ and CD4+ T cells oxidation, metabolic processes, cell cycle, and
apoptosis were influenced by therapy (S2 Table). Interestingly, the combination therapy led to
enhanced expression of proteins that participated in endoplasmic reticulum stress. This cellu-
lar process is known to regulate the activation and the functionality of CD4+ [40] and CD8+
[41] T cells. Also, proteins which negatively affect apoptosis were upregulated after combina-
tion treatment. Thus, changes in the activation status and inhibition of apoptosis may be key
cellular processes regulating the expansion of cytotoxic CD8+ and CD4+ effector T cells after
combination therapy. The data suggest that the immunopathology in acutely infected mice
Fig 3. CD8+ and CD4+ T cell activity after combination immunotherapy. Mice were infected with FV and were treated with DT and/or
blocking antibodies against PD-L1 and TIM-3 as indicated (Fig 1A). 18 days after infection inguinal lymph nodes (ILN) and mesenteric lymph
nodes (MesLN) were isolated and the flow cytometry analysis of CD8+ and CD4+ T cells was performed. Frequencies of CD8+ T cells expressing
CD43 (A) or positive for MHC class I H2-Db tetramers specific for FV GagL peptide (Tetr+) (B), or Eomes (C), or GzmB (D), are presented. The
frequencies of CD4+ T cells expressing CD62L- CD43+ phenotype (E), or positive for MHC class-II Ab FV-envelope specific tetramer (Tetr II+)
(F), or expressing Eomes (G), or GzmB (H) were detected. Each dot represents an individual mouse. Data were pooled from 3 to 5 independent
experiments with similar results. Statistically significant differences are indicated by asterisks (� < 0.05; �� < 0.005; ��� < 0.0005; one-way
ANOVA with a Tukey post-test).
https://doi.org/10.1371/journal.ppat.1008340.g003
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after therapy was mediated by cytotoxic T cells. In order to test this hypothesis, both CD4
+ and CD8+ T cells were depleted with monoclonal antibodies during the combination ther-
apy in FV-infected mice.
Taken together, this data confirmed that GzmB-mediated cytotoxicity of both CD4+ and
CD8+ T cells was critical for the development of immunopathology after combination
therapy.
Immunopathology is often associated with a “cytokine storm” since activated effector T
cells can produce large amounts of inflammatory cytokines. We, therefore, analyzed the levels
of 12 different cytokines in the serum of FV-infected mice receiving combination therapy at
different time points post infection to define the kinetics of the cytokine response. At 14 days
post infection (directly after treatment) very high concentrations of IL-2, IL-13, IL-10, IFNγ,
IL-6, and TNFα were observed (Fig 4E). During the following four days after treatment the
concentration of these cytokines constantly increased demonstrating an on-going inflamma-
tory response until the animals had to be euthanized at around 4 days post completion of ther-
apy. The high levels of the anti-inflammatory cytokines IL-10 and IL-13 most likely reflected
an insufficient counter-regulation to control the massive inflammatory response. This situa-
tion is characteristic for a “cytokine storm” [42] and reflects an unbalanced activation of the
immune system. Summarizing the data from our immunological studies leads to the following
conclusion: The combined immunotherapy blocking simultaneously the function of Tregs and
inhibitory receptors during an acute viral infection induced the expansion of cytotoxic effector
CD4+ and CD8+ T cells and the dysregulation of cytokine responses. The systemic immune
activation resulted in immunopathology, which was most apparent in the intestines of FV-
infected animals. Thus, combination immunotherapy targeting multiple immune checkpoint
pathways may be harmful in an acute viral infection.
The course of acute influenza virus infection in mice receiving
immunotherapy
Given that combination therapies are already used for the treatment of cancers in humans
[28], we next wanted to understand whether individuals receiving successful combination
therapies are at risk for severe immunopathology during an acute viral infection. For that we
used a clinically relevant human Influenza A (IV) virus mouse model.
The combination treatment with Treg depletion and blockade of PD-L1/Tim-3 was suc-
cessfully used previously for the therapy of chronic FV infection [25]. Chronic FV infection
does not induce any immunopathology in resistant mice and the combination therapy reduced
chronic viral loads with no induction of clinical symptoms. In order to utilize this model,
DEREG mice were infected with FV and rested for 60 days to establish viral chronicity.
Fig 4. Functional properties of CD8+ and CD4+ T cells after combination immunotherapy. A. Weight of non-treated FV-infected mice, and mice
infected and treated with DT and blocking antibodies against PD-L1 and TIM-3, and mice received additionally to combined treatment anti-CD4 or
anti-CD8 or both anti-CD4 and anti-CD8 antibody, and DEREG-GzmB KO mice treated with DT and blocking antibodies against PD-L1 and TIM-3.
For the depletion of CD4+ or CD8+ T cells mice were inoculated three times every other day starting on day 12 after FV infection. B. Redirect killing
of P815 cells that were loaded with anti-CD3 antibodies and co-incubated with CD4+ T cells (left), CD8+ T cells (middle) and CD4+ plus CD8+ T
cells (right) isolated from naïve mice, FV-infected mice and infected mice receiving combination treatment. Data were pooled from 3 independent
experiments with similar results. Statistically significant differences are indicated by asterisks (� < 0.05; �� < 0.005; ��� < 0.0005; non-parametric
Mann-Whitney test). CD3+ CD8+ CD43+ T cells and CD3+CD4+ CD43+ CD62L- T cells were sorted from spleens of FV-infected DEREG mice and
from FV-infected DEREG mice treated with DT and anti-PD-L1/anti-Tim-3 antibodies at 18 days post infection. After sorting cells were lysed for
proteome analysis. Volcano plot showing the comparison of protein expression in CD3+ CD8+ CD43+ (C) and CD3+CD4+CD43+CD62L- (D) T
cells isolated from non-treated and T cells with the same phenotype isolated from combination treated mice. Numbers of significantly reduced or
enhanced proteins in the group of treated mice are shown in volcano plots. Benjamini–Hochberg corrected one-way ANOVA was used for the
calculation of the p-values. E. FV infected mice from group received the combination treatment were bled at day 0, day 7, day 14 and day 18 after
infection and the concentration of cytokines was analyzed. Data were pooled from 2 independent experiments with similar results.
https://doi.org/10.1371/journal.ppat.1008340.g004
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Chronically infected mice were treated with DT for the elimination of Tregs and/or with anti-
PD-L1 antibodies (Fig 5A). In the current study we infected the mice intranasally with a low
dose of influenza virus A during the period of immunotherapy. Non-treated mice and mice
receiving only anti-PD-L1 antibodies controlled the low dose IV infection without obvious
influenza symptoms including any detectible loss of weight (Fig 5B). In contrast, mice receiv-
ing the combination treatment or mice depleted for Tregs started to lose weight at day 6 after
IV infection (Fig 5B). More than 20% loss of body weight was reached at day 12 after infection,
which was the indication to stop the experiment. Treg depleted mice and mice receiving com-
bination treatment were in poor condition, with liquid exudate in their lungs (Fig 5C), a typi-
cal symptom for advanced pneumonia. The analysis of lung homogenates for viral RNA
showed very low numbers of IV RNA copies in some mice depleted for Tregs and no detect-
able virus in mice from the other groups (Fig 5D). The absence of viral RNA in lung tissue pro-
vided evidence that the observed pathology of the lung was not directly caused by IV infection,
but suggested that it was mediated by immune cells. This was supported by the findings that
significantly enhanced frequencies of CD4+ T cells were present in bronchoalveolar lavage flu-
ids (BALF) from mice with lung pathology and weight loss (Fig 5F). In contrast, the percentage
of CD8+ T cells in BALF was not significantly different between the groups of mice (Fig 5E).
Thus, CD4+ T cells in BALF may be involved in the development of lung pathology in IV-
infected mice that were Treg depleted or that received combination therapy.
To further define the role of T cells in the observed immunopathology of the lung after IV
infection, we investigated the phenotype and functional properties of CD8+ and CD4+ T cells
isolated from mediastinal lymph nodes (mLN) or from BALF. Both CD4+ as well as CD8+ T
cells strongly proliferated (expressed Ki67) in mice that were IV-infected and received Treg
depleting DT or combination therapy (Fig 6A, 6B, 6G and 6H). This was mainly found in
mLN but also for cells from BALF of some mice. In addition, we also stained T cells for the sur-
rogate markers of cytotoxicity GzmB and Eomes in mLN and BALF. The numbers of T lym-
phocytes expressing markers of cytotoxicity were highest in Treg depleted IV-infected mice as
well as in animals that received combination therapy (Fig 6C–6L). Overall, the highest num-
bers of T cells expressing GzmB or EOMES were found in mice treated with the combination
therapy, which was in many cases significantly higher than the numbers in mice receiving
either treatment alone. Thus, the lung pathology in mice was associated with the expansion of
CD4+ and CD8+ T cells with cytotoxic potential in mLN and in lung tissue.
The current findings demonstrate that the infection of mice with a low dose of IV resulted
in severe immunopathology of the lung under immune checkpoint blocking therapy. Vaccina-
tion against IV prevents severe symptoms after influenza infection in humans. In order to test
whether a vaccination would also prevent the development of immune-mediated IV-induced
pathology after combination therapy in mice, the following experiment was proposed. Naïve
mice were vaccinated three times with inactivated IV every two weeks (Fig 7A). Two weeks
after the last immunization combination treatment was started. On the following day mice
were infected with IV and their weight was followed to monitor the development of pathology
(Fig 7B). These experiments were performed without previous FV infection in both the vacci-
nated as well as the non-vaccinated control group. IV-infected mice without treatment showed
transient weight loss between day four and day ten after infection, but fully recovered. Loss of
weight in the group of mice with combination therapy also started on day four and progressed
until the animals had to be euthanized on day 13. In contrast, vaccinated mice did not show
any significant reduction of body weight under IV infection and therapy. Thus, pre-therapy
vaccination against IV may be an option to reduce the risk of virus-induced immunopathology
during immune checkpoint therapy.
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Fig 5. Lethality of chronic FV infected mice after Treg depletion and/or blocking of inhibitory pathways and infected with low doses of influenza virus. A.
Chronically FV infected mice were treated with DT for Treg depletion and/or treated with anti-PD-L1 antibody. One day after starting the treatment mice were
infected with IV. The weight of the analyzed group of mice (B) and the lungs of non-treated and combination treated mice (C). The numbers of RNA copies of IV in
lung homogenate (D). The dashed line reflects the detection limit of the method. The percentage of CD4+ (E) and CD8+ (F) T cells in the BALF cells was calculated by
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Cytotoxic CD4+ and CD8+ T cells in the peripheral blood of melanoma
patients developing intestinal autoimmune pathologies under immune
checkpoint combination therapy
Our results from the combination therapy in acutely infected animals provide evidence that
immunopathology was caused by expanded CD4+ and CD8+ T cells that produced gran-
zymes. Immune-related adverse events (IrAE) are the main complication during the treatment
of different malignancies with checkpoint blockers. Interestingly, treatment with anti-CTLA-4
antibodies was reported to deplete Tregs, which express high levels of CTLA-4 [43,44]. Thus,
the treatment of melanoma patients with a combination of nivolumab (anti-PD-1 antibody)
and ipilimumab (anti-CTLA-4 antibody) seems to have similar immunological effects as our
combination therapy described above. Moreover, about 95.5% of patients receiving combina-
tion treatment develop IrAE symptoms of different grades [45]. To study this in more detail,
PBMC samples of eleven melanoma patients were obtained before combination therapy with
nivolumab and ipilimumab and after the manifestation of gastrointestinal IrAE symptoms
(five ± two week after therapy start). The clinical data of the analyzed patients are summarised
in S3 Table. Most patients (eight out of eleven) had disease control with complete, partial, sta-
ble or mixed responses to therapy. However, the development of severe IrAE symptoms led to
premature termination of the combination therapy with ipilimumab and nivolumab in eight
patients. Thereafter, patients were treated with corticosteroids alone or in combination with
additional immunosuppressive drugs. No significant changes in the frequencies of lympho-
cytes or myeloid cells were associated with the development of IrAE during combination ther-
apy (S3 Table). The phenotype of CD4+ and CD8+ T cells and the intracellular expression of
GzmA and GzmB in these cells were analyzed before therapy and at the manifestation of ther-
apy-induced symptoms (IrAE). The frequency of CD8+ T cells with an effector memory
(CD45RO+ CCD7-) phenotype was significantly enhanced after treatment (Fig 8A and 8B).
The frequency of effector CD8+ T cells (CD45RO- CCR7-) was also enhanced after treatment
in seven out of eleven investigated patients (Fig 8A and 8C). In addition, the percentage of
effector memory CD8+ T cells expressing GzmA or GzmB was significantly increased (Fig 8D
and 8E). In the population of effector CD8+ T cells only the production of GzmB was
enhanced (Fig 8F and 8G). The populations of circulating CD4+ T cells with effector memory
or effector phenotype were significantly expanded in all investigated patients under treatment
(Fig 8H–8J). The frequencies of CD4+ T cells producing GzmA and GzmB in both effector T
cell subpopulations were enhanced (Fig 8K–8N), but in the population of effector CD4+ T
cells differences for GzmB were not significant. Thus, similar to our animal experiments, a
combination therapy in melanoma patients led to the expansion of effector CD4+ and CD8
+ T cells showing enhanced production of granzymes.
Discussion
An acute virus infection strongly activates the immune system and multiple inhibitory mecha-
nisms are necessary to counterbalance this response in infected organs or even systemically.
Tregs and inhibitory receptors are the two most powerful controllers of the activation and
function of T lymphocytes in infectious diseases [8,46]. Both of these inhibitory mechanisms
work independently of each other and suppress the differentiation and expansion of cytotoxic
CD8+ T cells during chronic infection. Thus, the combination of depletion/inhibition of Tregs
flow cytometry. Each dot represents an individual mouse. Data were pooled from 2 to 3 independent experiments with similar results. Statistically significant
differences are indicated by asterisks (�� < 0.005; one-way ANOVA with a Tukey post-test).
https://doi.org/10.1371/journal.ppat.1008340.g005
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together with the blockage of inhibitory receptors results in a strong enhancement of antiviral
T cell responses and was proposed as a treatment of chronic infections or cancers [28]. How-
ever, if this treatment was performed during acute viral infections it resulted in severe immu-
nopathology and death of treated animals. The lethality was associated with a systemic
activation and expansion of cytotoxic CD8+ and CD4+ T cells. Immune responses against
pathogens are regulated by different stimulatory and inhibitory pathways to reach a balance
between the elimination of virus-infected cells and the prevention of immunopathology,
Fig 6. Characterization of CD8+ T cells and CD4+ T cells isolated from mediastinal lymph nodes and from
bronchoalveolar lavage. Mice chronic infected with FV were treated with DT (DEREG mice) and/or blocking antibodies
against PD-L1. One day after the start of treatment mice were infected with IV and, 12 days after IV infection, were killed
and mediastinal LN and BALF were analyzed by flow cytometry. Frequencies of CD8+ T cells positive for Ki67+ in MLN
(A) and in BALF (B), numbers of CD8+ T cells positive for Eomes in MLN (C) and in BALF (D), and numbers of CD8+ T
cells producing GzmB in MLN (E) and in BALF (F). Frequencies of CD4+Foxp3- T cells positive for Ki67 in MLN (G) and
in BALF (H), numbers of CD4+Foxp3- T cells positive for Eomes in MLN (I) and in BALF (J), and numbers of CD4
+Foxp3- T cells producing GzmB in MLN (K) and in BALF (L). Each dot represents an individual mouse. Data were
pooled from 2 to 4 independent experiments with similar results. Statistically significant differences are indicated by
asterisks (� < 0.05; �� < 0.005; ��� < 0.0005; one-way ANOVA with a Tukey post-test).
https://doi.org/10.1371/journal.ppat.1008340.g006
Fig 7. Vaccination prevents the development of immune-mediated pathology. DEREG mice were immunized with
an inactivated influenza virus and treated with DT and anti-PD-L1 antibody (A). Weight reduction of mice infected
with IV (black line), IV-infected and treated (blue line), and vaccinated, IV-challenged and treated (red line) (B). Data
were pooled from 2 independent experiments with similar results. Statistically significant differences are indicated by
asterisks (��� < 0.0005; non-parametric Mann-Whitney test).
https://doi.org/10.1371/journal.ppat.1008340.g007
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Fig 8. Characterization of CD8+ T cells and CD4+ T cells from PBMCs of melanoma patients with symptoms of AiRE after checkpoint blocking therapy.
Multiparameter flow cytometry was used for the analysis of CD8+ and CD4+ T cell differentiation and production of GzmA and GzmB. Representative dot plots of CD8
+ T cells of a melanoma patient before combination therapy and during the therapy (A). Percentage of CD8+ T cells with the phenotype of effector-memory (EM)
(CD45RO+ CCR7-) (B) or effector cells (E) (CD45RO- CCR7-) (C). Percentage of EM CD8+ produced GzmA (D) or GzmB (E); percentages of E CD8+ producing
GzmA (F) or GzmB (G). Representative dot plots of CD4+ T cells of a melanoma patient before combination therapy and during the therapy (H). Percentage of CD4+ T
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which may result in the failure of infected organs. The recognition of molecular viral patterns
by infected and innate immune cells induces several mechanisms mobilizing the immune sys-
tem [47] including the secretion of proinflammatory cytokines and type I IFNs. The expan-
sion, functional differentiation and apoptosis of stimulated T cells during an acute infection
are strictly controlled by different immunomodulatory mechanisms. Tregs and inhibitory
receptors are important players of this immune regulation [48–50]. This regulation is also
involved in the selection of T cells with high antiviral specificity. In our current experiments,
numbers of virus-specific CD4+ and CD8+ T cells only moderately increased after combina-
tion therapy during acute FV infection, at least those for the two immunodominant T cell epi-
topes we analyzed. Thus, improved functional properties of T cells due to immune checkpoint
blockers seem to be more important for the observed development of immunopathology in
mice. However, an acute virus infection was required to tip the balance towards immunopa-
thology during an ongoing combination immune checkpoint blocking therapy. Is this a prob-
lem that cancer patients undergoing combination therapy face? Up to now there is no
published data on frequencies and consequences of acute infections in such patients. However,
the most successful combination checkpoint blocking therapy in cancer patients is very similar
to what we did in our mouse studies. Combination treatment with antibodies against CTLA-4
and PD-1/PD-L1 was very potent in inducing tumor regression [51]. It was shown that the
anti-CTLA-4 antibodies, currently used for the treatment of melanoma and lung cancer
patients, significantly reduce the numbers of Tregs [52,53], and it is discussed if this is the
mechanism how they actually activate the anti-tumor immune response. Interestingly, the
main complications during the treatment of patients with PD-1/PDL-1 blocking antibodies
and with Treg-reducing CTLA-4 antibodies [28,29] are autoimmune disorders that are fre-
quently manifested in the gut [51]. These disorders, also referred to as immune-related adverse
events (irAE), are the main indication for termination of treatment with immune checkpoint
blockers. In some cases, combination therapy led to irAE with fatal outcome [54]. It is possible,
but not so far not documented, that seasonal acute viral infections may have contributed to
severe irAE pathology. Our mouse data suggest that prevention or rapid control of acute infec-
tions might be important in cancer patients undergoing combination therapy with several
immune checkpoint inhibitors. One obvious difference between our mouse data and the situa-
tion in human patients is that the anti-CTLA-4 antibody does only result in a partial depletion
of Tregs in humans [29], whereas DT injection into DEREG mice results in a complete Treg
depletion that lasts at least for several days. This might induce more severe (lethal) pathology
in the mouse model after an acute infection during combination therapy compared to human
patients. In the future, the population of Tregs may be also be affected by other immunothera-
pies that are currently tested in clinical trials or preclinical experiments. Antibodies specific for
CCR4 (C-C chemokine receptor type 4), GITR (glucocorticoid-induced TNF-receptor family
related protein), or OX40 (Tumor necrosis factor receptor superfamily, member 4, CD134)
[55] all reduce Treg responses. Moreover, some conventional chemotherapeutics for the treat-
ment of different types of cancers (summarized in review [56]) also reduce the numbers of
Tregs and/or the functionality of these cells. The combination of such drugs with immune
checkpoint blockers may therefore also induce the risk of severe pathology during an acute
infection.
cells with the phenotype of EM (CD45RO+ CCR7-) (I) or E (CD45RO- CCR7-) (J). Percentage of EM CD4+ T cells producing GzmA (K) or GzmB (L); percentages of E
CD4+ T cells producing GzmA (M) or GzmB (N). Each dot represents data from an individual patient. Data from the same patient are connected. Statistically
significant differences are indicated by asterisks (� < 0.05; paired nonparametric t-test).
https://doi.org/10.1371/journal.ppat.1008340.g008
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In the main part of this study we used a murine virus to expore immunopathology during
immune checkpoint therapy. In order to investigate whether a similar pathology develops
under combination therapy after infection with a human virus we inoculated mice with low
doses of IV. These animals were chronically infected with FV to characterize how a successful
therapy against a chronic infection tips towards immunopathology under the condition of an
acute virus infection. In these experiments, animals that were depleted for Tregs as well as
those receiving combination therapy developed severe pneumonia even though IV replication
was efficiently controlled. In the case of IV, the pathology was mainly observed in the lung, the
main target organ of viral replication and subsequent antiviral immune responses. Again, the
complete depletion of Tregs in the DEREG model might have contributed to the severe pathol-
ogy after single immunotherapy. However, also in this model maximum immune activation
was found in mice receiving combination therapy. It was recently shown that Tregs in the lung
of IV infected mice did not only have a suppressive activity on effector T cells [57] but were
also necessary for the repair of lung tissue damaged by the virus. The elimination of Tregs
potentiated the damage of the lung and the severity of lung pathology after IV [57] infection,
but also during Respiratory Syncytial Virus (RSV) infection [58,59]. This suggests that Tregs
might be especially important in protecting lung tissue during an acute infection and that
immunotherapies targeting Tregs might pose a special risk for severe lung infections. Interest-
ingly, the IV vaccination of mice prior to immunotherapy and IV challenge prevented the
development of lethal immunopathology (Fig 7B). Thus, vaccination may be an important
prophylactic option to prevent virus-mediated T cell activation and the development of irAE
complications during immunotherapy. Contradictory results from two recent studies which
analyzed the effects of IV vaccination during anti-PD-1 therapy of patients with lung cancer
were published [60, 61]. In one study an enhanced frequency of irAE after IV vaccination was
observed [60], while another study reported no differences between vaccinated and non-vacci-
nated patients [61]. These studies only investigated the direct effects of vaccination but not the
possible protection from infection. However, our data suggest that vaccination prior to immu-
notherapy might be more appropriate to prevent pathologies than during therapy.
Another approach might be the prophilactic neutralization of TNF-α to reduce the symp-
toms of irAE during checkpoint blockade [62]. The enhanced production of different cyto-
kines including TNF-α was also observed in our study (Fig 4E) which suggests that anti-TNF-
α treatment might prevent the development of pathology. Type I Interferon responses are also
often associated with immunopathology[63], but so far no data exists to answer the question if
they contribute to irAE during checkpoint therapy.
The immunopathology seen in our mouse experiments was likely associated with the
expansion of cytotoxic T cells. Previously it was shown that expanded LCMV-induced CD8
+ T cells were responsible for the development of immunopathology in mice [64]. The exhaus-
tion of such cells is a possible mechanism to reduce pathology in infected organs, as they can
be very harmful for many host cells and have to be tightly controlled during an ongoing
immune response. In particular, the massive expansion of cytotoxic CD4+ T cells was fre-
quently reported to be associated with immunopathology. An accumulation of cytotoxic CD4
+ T cells was observed in patients with multiple sclerosis (MS) [65,66], inflammatory bowel
disease (IBD) [67], rheumatoid arthritis (RA) [68], and ankylosing spondylitis [69]. Interest-
ingly, Human Parvovirus B19 specific GzmB producing CD4+ T cells may contribute to RA
and systemic lupus erythematosus (SLE) associated with chronic B19 infection [70]. Thus,
CD4+ T cell cytotoxicity seems to be a hallmark of immunopathology. During acute FV infec-
tion, the CD4+ T cell cytotoxicity is controlled/suppressed by Tregs [34]. Also immune check-
point receptors have been shown to regulate the differentiation of cytotoxic CD4+ T cells [71].
This implies that CD4+ cytotoxicity is be tightly controlled because these cells have the
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potential to induce severe damage in infected or even healthy tissue. Our current data indicate
that several different immune checkpoints contribute to this control.
Taken together, seasonal viral infections circulating in the human population are often
asymptomatic or induce minimal symptoms. However, an acute infection of cancer patients
undergoing combination therapy may provoke a systemic activation of the immune system
with progression to immunopathology. Another unanswered question is whether latent
human viruses, like CMV, EBV, HSV may contribute to the development of immunopathol-
ogy during the treatment with checkpoint blockers. One study actually reported a reactivation
of latent CMV during checkpoint blocking therapy [72]. The observations described in the
current study provide a warning for current and future treatments targeting regulatory
immune mechanisms, especially those affecting Tregs. Enhanced numbers of GzmB producing
CD4+ and CD8+ T cells in tumor patients after combination treatment with antibodies against
PD-1 and CTLA-4 have previously been described [73], but this study did not perform a
detailed characterization of the GzmB producing cells. Our data indicate that T cells producing
granzymes during combination therapy express an effector or effector-memory phenotype.
The expansion of these cells was timely associated with the appearance of irAE symptoms.
Although our human study does not provide a causative link between granzyme-producing
CD4+ or CD8+ T cells and irAE, we can speculate that these CTLs might be potentially harm-
ful and their responses may be accelerated during virus infections. This hypothesis was
recently supported by a case report of fatal encephalitis that developed after anti-PD-1 therapy
in a melanoma patient [74]. The injured regions of the patient’s brain showed a massive expan-
sion of EBV-specific CD4+ T cells producing GzmB. Based on these data, it can be important
to monitor the numbers of effector and effector-memory CD4+ and CD8+ T cells and their
production of GzmB during the treatment with immune checkpoint blockers. Another practi-
cal conclusion from the current data is the necessity to protect patients from acute viral infec-
tions by vaccination before treatment is started.
Methods
Ethics statement
Animal experiments were performed in strict accordance with the German regulations of the
Society for Laboratory Animal Science (GV-SOLAS) and the European Health Law of the Fed-
eration of Laboratory Animal Science Associations (FELASA). The protocol was approved by
the North Rhine-Westphalia State Agency for Nature, Environment and Consumer Protection
(LANUV). All efforts were made to minimize suffering. Samples from adult patients were col-
lected after written informed consent. Studies on human material were approved by the insti-
tutional review board of the University of Duisburg-Essen.
Mice
Inbred C57BL/6 (B6) and DEREG [30] mice were maintained under pathogen free conditions.
Experiments were done using mice (H-2b/b, Fv1b/b, Fv2r/r) on C57BL/6 background that are
resistant to FV-induced leukemia. All mice were females of 8–12 weeks of age at the beginning
of the experiments.
Virus and viral infection
The FV stock used in these experiments was FV complex containing B-tropic Friend murine
leukemia helper virus (F-MuLV) and polycythemia-inducing spleen focus-forming virus [75].
The stock was prepared as a 10% spleen cell homogenate from BALB/c mice infected 14 days
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previously with 3,000 spleen focus-forming units of non-cloned virus stock. Experimental
mice were injected intravenously with 20,000 spleen focus-forming units of FV complex.
Mice, which were at least 30 days infected with 20,000 spleen focus-forming units of FV
complex, were anesthetized by ketamine/xylazin (25μl) and intranasally infected with 15 PFUs
of influenza virus A/PR/8/34.
Inactivation of influenza virus
A high-titered (10^9 pfu/ml), chicken egg-grown stock of PR/8/34 was treated for 24 h with
0.1% β-propiolactone (Acros Organics) at room temperature, followed by dialysis for 24 h
against HNE buffer (5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4) at 4˚ C.
Immunization of mice and IV challenge
Mice were immunized i.p. with 1μg of inactivated IV diluted in 300 ml PBS on days 0, 14, and
28. On day 42 after initial immunization, mice were anesthetized by ketamine/ xylazine and
challenged intranasally with 15 PFUs influenza virus A/PR/8/34 (50 ml).
In vivo blockade
For blockade of the PD-1 pathway in acute FV-infected mice, 200μg rat anti-mouse PD-L1 Ab
(10F.9G2; BioXCell) was administered intraperitoneally every third day for 3 times. To block
the Tim-3 pathway, 100μg rat anti-mouse Tim-3 Ab (RMT3-23; BioXCell) was administered
intraperitoneally every other day for 4 times (Fig 1A). The T cell responses and viral loads
were analyzed one day post treatments or 4 days post treatments (Fig 1A).
During chronic FV infection mice were treated with 200μg rat anti-mouse PD-L1 Ab
(10F.9G2; BioXCell) intraperitoneally every third day for 3 times.
Re-directed killing assay
Measurement of the cytotoxic activity of CD4+ and CD8+ T cells was performed by using a
previously described re-directed killing assay [39]. CD4+ and CD8+ T cells isolated with mag-
netic beats were co-incubated for 5 hours with anti-mouse CD3 antibody-loaded P815 target
cells. After incubation the activity of LDH in the supernatant was measured using Pierce LDH
Cytotoxicity Assay Kit (Thermo Sciantific). The percentage of target cell elimination was cal-
culated as % cell lysis = (experimental–effector spontaneous–low control) x 100/ (high con-
trol–low control). Cytotoxicity assays were performed with varying effector cell (E) to target
cell (T) ratios, and percentages of lysis are reported as the mean ± SD of triplicate samples.
Infectious center assays
Infectious center assays were performed as described previously [76].
Determination of lung influenza virus copy number
Lungs were collected on day 12 after IV challenge; they were homogenized in PBS containing
0.3% BSA and centrifuged for 8 min. Viral RNA was isolated from 140 μl lung homogenates
using the QIAamp Viral RNA Mini Kit (Qiagen) according to the manufacturer’s instructions.
The quantity of viral RNA was determined by real-time RT-PCR (RT-quantitative PCR) using
the QuantiTect Probe RT-PCR Kit (Qiagen) with SYBR-Green. A conserved sequence in the
matrix gene of influenza A virus was detected using the specific primers described elsewhere
(50-CTTCTAACCGAGGTCGAAACG-30 + 50-AGGGCATTTTGGACAAAG/TCGTCTA-30)
(19).
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Isolation of lamina propria lymphocytes from the small intestine
Lamina propria lymphocytes were isolated from small intestines as described previously [77].
In brief, small intestines were rinsed extensively with PBS, and residual mesenteric fat tissue
and Peyer‘s patches were resected. Intestines were cut open longitudinally and sliced into
small pieces. Under constant stirring at 37˚C, the intestines were incubated twice in PBS con-
taining 3 mmol/L EDTA. EDTA was removed by incubating the intestines twice in RPMI-
1640 medium containing 1% FCS, 1 mmol/L EGTA, and 1.5 mmol/L MgCl2. Small intestines
were digested in RPMI-1640 containing 20% FCS and 100 U/mL collagenase IV (Sigma-
Aldrich) at 37˚C for 30 minutes. To obtain single cells, the remaining suspensions were passed
through 30-μm cell strainer and washed with RPMI medium.
Immunohistochemistry of intestine
Immunofluorescence analyses were performed on snap-frozen tissues. Intestine sections were
stained for CD8 T cells (anti-CD8; company, clone 53–6.7, eBiosciences), CD4 T cells (anti-
CD4; clone RM4-5, eBiosciences)). Scale bar indicates 100μm, as indicated in the figure
legend.
Cell surface and intracellular staining by flow cytometry
Surface and intracellular staining were performed as described previously [20]. For surface
staining were used antibodies specific against mice CD3 (17A2), CD4 (RM4-5), CD8 (53–6.7),
CD11a (M17/4) CD43 (1B11), CD44 (IM7), CD62L (MEL-14), CD69 (H1.2F3), CD127
(AFR134), KLRG1 (2F1), and for intracellular staining were used antibody specific against
mice EOMES (Dan11mag), Foxp3 (FJK-16S), GzmB (GB11), Ki67 (B56), and T-bet (4B10)
produced by eBiosciences or BioLegend. For surface staining of human cells were used anti-
bodies specific against human CD3 (SK7), CD4 (OKT4), CD8 (HIT8a), CD45RO (UCHL1),
CCR7 (G043H7), and for intracellular staining were used antibody specific against human
GzmA (CB8) and GzmB (GB11) produced by BioLegend.
Data were acquired on a LSR II flow cytometer (Becton Dickinson) from 350,000–500,000
lymphocyte-gated events per sample. Analyses were done using FACSDiva software (Becton
Dickinson) and FlowJo software (Treestar).
Cytokine staining
Cytokine levels were estimated using the LegendPlex (BioLegend) and ProcartaPlex Mouse
Th1Th2 essential 6 plex (EPX060-20831-S1, Affymetrix), following manufacturers instruc-
tions. The ProcartaPlex assay was measured by Luminex, using Luminex IS software.
Lymphocyte depletion
To deplete Tregs, FV-infected DEREG mice were injected intraperitoneally with diphtheria
toxin (Merck, Darmstadt, Germany), diluted in endotoxin-free PBS. 0.5 μg DT was inoculated
every third day for 3 times. CD4+ and CD8+ T cell depletions were performed essentially as
described previously [50]. Mice were inoculated three times every other day, starting on day 12
after FV infection. The treatment depleted 92% of CD4+ T cells and 87% of CD8+ T cells.
Tetramers and tetramer staining
For detection of Db-GagL-specific CD8+ T cells, nucleated spleen cells were stained with PE
labeled MHC class I H2-Db tetramers specific for FV GagL peptide [33,78] (Beckman Coulter,
Marseille, France).
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MHC class-II tetramer (Tet II) Ab-restricted F-MuLV-envelope epitope (H19-Env)
(EPLTSLTPRCNTAWNRLUL) staining of FV-specific CD4+ T cells was performed as previ-
ously described [35].
For detection of CD8+ T cells specific to the nucleoprotein (NP366-374) of IV the staining
with PE labeled H2Db NP366-374 tetramers was performed [79,80].
Label-free quantitative mass spectrometry
Cells were lysed by sonication (6 10-s pulses on ice) in sample buffer (50 mM NH4HCO3;
0.1% Rapigest). Protein isolation, digestion, amino acid analysis, and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis were performed by following previously
described procedures [81]. Progenesis QI for proteomics (v. 2.0.5387.52102; Non-linear
Dynamics, Newcastle upon Tyne, UK) and Proteome Discoverer (v. 1.4; Thermo Scientific,
Bremen, Germany) software packages were used for protein quantification and identification,
respectively. For protein identification, LC-MS/MS runs were searched against the UniProt-
SwissProt database (Release 2014_10; v. 2.5; 546,790 sequences) with taxonomy restriction to
mus musculus. Further search parameters matched previously reported ones [81]. Non-unique
peptides associated to more than one protein accession were not used for quantification. Dif-
ferentially expressed proteins (p< 0.05) were functionally annotated using the Database for
Annotation, Visualization, and Integrated Discovery (DAVID, ver. 6.8) [82,83].
Statistical analysis
Statistics comparing the two groups were done using the unpaired non-parametric t-test or
Mann-Whitney t-test. When more than two groups were compared, a one-way ANOVA was
used with a Tukey post-test. (GraphPad Prism software; GraphPad Software Inc., San Diego,
USA). For statistical analysis of proteomics data, normalized protein abundances were
exported from Progenesis QI software and transformed using arcsinh-function. Using an in-
house written R script (R Foundation for Statistical Computing, Vienna, Austria), Benjamini–
Hochberg corrected one-way ANOVA was used for the calculation of the FDR-corrected p-
values as described earlier [81].
Supporting information
S1 Fig. Representative dot plots of CD8+ and CD4+ T cells after combination therapy.
DEREG mice were infected with FV and treated with DT and/or blocking antibodies against
PD-L1 and TIM-3. Flow cytometry was used for the determination of spleen CD8+ T cells
which are expressing CD43 (A), positive for MHC class I H2-Db tetramers specific for FV
GagL peptide (Tetr+) (B), and producing the GzmB (C), and the percentages of CD4+ T cells
producing the GzmB (D). Representative dot plots of one mice per every group are presented.
(TIF)
S2 Fig. Inflammation in liver, pancreas, and stomach. Hematoxylin and eosin staining of
paraffin sections of liver, pancreas, and stomach of mice with combined DT and PD-L1/Tim3
treatment and control mice. The images were captured at 40x magnification (liver and pan-
creas) and 20x magnification (stomach).
(TIF)
S3 Fig. Immunofluorescence analysis of intestine sections. C57BL6 (groups of FV infected
mice without treatment and mice with PD-L1/Tim3 treatment) and DEREG (groups with DT
treatment and group of mice with combined DT and PD-L1/Tim3 treatment were infected
with FV and were treated with DT and/or blocking antibodies against PD-L1 and TIM-3 as
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indicated during the second week of infection. The intestine sections were stained for DAPI
(blue), CD4+ T cells (red), and CD8+ T cells (green). Fluorescent images were captured at 20x
magnification using KeyenceBZ-9000E microscope.
(TIF)
S4 Fig. Characterization of CD8+ T cells and CD4+ T cells isolated from inguinal lymph
nodes. Mice were infected with FV and were treated with DT and/or blocking antibodies
against PD-L1 and TIM-3 as indicated (Fig 1A). 18 days after infection mesenteric lymph
nodes were isolated and the flow cytometry analysis of CD8+ and CD4+ T cells was per-
formed. Mean percentages of CD8+ T cells (A) and CD4+ T cells (B) expressing T-bet, CD43,
CD44, CD11a, KLRG1, Ki67, CD69, or negative for CD62L and for CD127 from 5–8 mice are
presented. Data were pooled from 2 or 3 independent experiments with similar results.
(TIF)
S1 Table. Global proteome analysis of expanded CD4+ and CD8+ T cells. Mice were
infected with FV and were treated with DT and blocking antibodies against PD-L1 and TIM-3
as indicated (Fig 1A). At 18 days post infection CD3+CD8+CD43+ T cells and CD3+CD4
+CD43+CD62L- T cells were sorted from the spleens of FV-infected DEREG mice and from
infected DEREG mice treated with DT plus anti-PD-L1/Tim-3 antibodies. Cells were lysed
and subjected to proteome analysis performed by label-free quantification using liquid chro-
matography and tandem mass spectrometry (LC-MS/MS).
(XLSX)
S2 Table. Clustering analysis of differently expressed proteins. Mice were infected with FV
and were treated with DT and blocking antibodies against PD-L1 and TIM-3 as indicated (Fig
1A). At 18 days post infection CD3+CD8+CD43+ T cells and CD3+CD4+CD43+CD62L- T
cells were sorted from the spleens of FV-infected DEREG mice and from infected DEREG
mice treated with DT plus anti-PD-L1/Tim-3 antibodies. Cells were lysed and subjected to
proteome analysis performed by label-free quantification using liquid chromatography and
tandem mass spectrometry (LC-MS/MS). Differently expressed proteins were analyzed with
the Gene Ontology enrichment tool (GO analysis).
(XLSX)
S3 Table. Clinical data of patients. Clinical data of a melanoma patients treated with a combi-
nation of nivolumab (anti-PD-1 antibody) and ipilimumab (anti-CTLA-4 antibody).
(XLSX)
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